BMS IM027-068 IPF A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Bristol-Myers Squibb Company
Start Date
November 14, 2023
End Date
June 14, 2028
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Bristol-Myers Squibb Company
Start Date
November 14, 2023
End Date
June 14, 2028